[186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: A comparison of the efficacy in experimental human ovarian cancer

Els Kievit, Frank B. Van Gog, Hennie M M Schlüper, Guus A M S Van Dongen, Herbert M. Pinedo, Epie Boven

Research output: Contribution to journalArticle

Abstract

We have investigated whether [186-Re]-labeled chimeric monoclonal antibody 323/A3 (MAb c-323/A3) is as effective as [186Re]-labeled mouse 323/A3 (m-323/A3) in the growth inhibition of human ovarian cancer xenografts OVCAR-3 and FMa. [186Re] was conjugated to MAbs with the use of the chelate S-benzoylmercaptoacetyltriglycine (S-benzoyl-MAG3). The maximum number of metal-MAG3 groups that could be conjugated to one MAb molecule accepting a minimal initial increase of the blood clearance (15%) was 8.5 and 2.9 for c-323/A3 and m-323/A3, respectively. With these molar ratios the immunoreactivity of both MAbs was maintained. An inverse relationship was observed between the protein dose of c-323/A3 and its blood clearance. Both [186Re]-c-323/A3 and [186Re]-m-323/A3 were comparable in the inhibition of the tumor growth when higher protein doses were used. Together with the expected lower immunogenicity, our results imply that c-323/A3 is preferable for use in [186Re]-radioimmunotherapy in ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalNuclear Medicine and Biology
Volume25
Issue number1
DOIs
StatePublished - Jan 1998
Externally publishedYes

    Fingerprint

Keywords

  • [Re]
  • Mouse and Chimeric MAb 323/A3
  • Ovarian cancer
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this